Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Case Rep
Asıl Yazarlar: Nagashima, Kana, Kikuchi, Shohei, Iyama, Satoshi, Fujita, Chisa, Goto, Akari, Horiguchi, Hiroto, Kobune, Masayoshi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Case Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7069848/
https://ncbi.nlm.nih.gov/pubmed/32185037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2688
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller